key: cord-0971490-ylj5fdfs
authors: Bousquet, Jean; Agache, Ioana; Blain, Hubert; Jutel, Marek; Ventura, Maria Teresa; Worm, Margitta; Del Giacco, Stefano; Benetos, Athanasios; Bilo, M. Beatrice; Czarlewski, Wienczyslawa; Abdul Latiff, Amir Hamzah; Al‐Ahmad, Mona; Angier, Elizabeth; Annesi‐Maesano, Isabella; Atanaskovic‐Markovic, Marina; Bachert, Claus; Barbaud, Annick; Bedbrook, Anna; Bennoor, Kazi S; Berghea, Elena Camelia; Bindslev‐Jensen, Carsten; Bonini, Sergio; Bosnic‐Anticevich, Sinthia; Brockow, Knut; Brussino, Luisa; Camargos, Paulo; Canonica, G Walter; Cardona, Victoria; Carreiro‐Martins, Pedro; Carriazo, Ana; Casale, Thomas; Caubet, Jean‐Christoph; Cecchi, Lorenzo; Cherubini, Antonio; Christoff, George; Chu, Derek K; Cruz, Alvaro A; Dokic, Dejan; El‐Gamal, Yehia; Ebisawa, Motohiro; Eberlein, Bernadette; Farrell, John; Fernandez‐Rivas, Montserrat; Fokkens, Wytske J; Fonseca, Joao A; Gao, Yadong; Gavazzi, Gaëtan; Gawlik, Radolslaw; Gelincik, Asli; Gemicioğlu, Bilun; Gotua, Maia; Guérin, Olivier; Haahtela, Tari; Hoffmann‐Sommergruber, Karin; Hoffmann, Hans Jürgen; Hofmann, Maja; Hrubisko, Martin; lenaIllario, Madda; Irani, Carla; Ispayeva, Zhanat; Ivancevich, Juan Carlos; Julge, Kaja; Kaidashev, Igor; Khaitov, Musa; Knol, Edward; Kraxner, Helga; Kuna, Piotr; Kvedariene, Violeta; Lauerma, Antti; Le, Lan TT; Le Moing, Vincent; Levin, Michael; Louis, Renaud; Lourenco, Olga; Mahler, Vera; Martin, Finbarr C; Matucci, Andrea; Milenkovic, Branislava; Miot, Stéphanie; Montella, Emma; Morais‐Almeida, Mario; Mortz, Charlotte G; Mullol, Joaquim; Namazova‐Baranova, Leyla; Neffen, Hugo; Nekam, Kristof; Niedoszytko, Marek; Odemyr, Mikaëla; O’Hehir, Robyn E; Okamoto, Yoshitaka; Ollert, Markus; Palomares, Oscar; Papadopoulos, Nikolaos G.; Panzner, Petr; Passalacqua, Gianni; Patella, Vincenzo; Petrovic, Mirko; Pfaar, Oliver; Pham‐Thi, Nhân; Plavec, Davor; Popov, Todor A; Recto, Marysia T; Regateiro, Frederico S; Reynes, Jacques; Roller‐Winsberger, Regina E; Rolland, Yves; Romano, Antonino; Rondon, Carmen; Rottem, Menachem; Rouadi, Philip W; Salles, Nathalie; Samolinski, Boleslaw; Santos, Alexandra F; Serpa, Faradiba Sarquis; Sastre, Joaquin; Schols, Jos M.G.A.; Scichilone, Nicola; Sediva, Anna; Shamji, Mohamed H.; Sheikh, Aziz; Skypala, Isabel; Smolinska, Sylwia; Sokolowska, Milena; Sousa‐Pinto, Bernardo; Sova, Milan; Stelmach, Rafael; Sturm, Gunter; Suppli Ulrik, Charlotte; Todo‐Bom, Ana Maria; Toppila‐Salmi, Sanna; Tsiligianni, Ioanna; Torres, Maria; Untersmayr, Eva; Urrutia Pereira, Marilyn; Valiulis, Arunas; Vitte, Joana; Vultaggio, Alessandra; Wallace, Dana; Walusiak‐Skorupa, Jolanta; Wang, De‐Yun; Waserman, Susan; Yorgancioglu, Arzu; Yusuf, Osman M; Zernotti, Mario; Zidarn, Mihaela; Chivato, Tomas; Akdis, Cezmi A; Zuberbier, Torsten; Klimek, Ludger
title: Management of anaphylaxis due to COVID‐19 vaccines in the elderly
date: 2021-04-02
journal: Allergy
DOI: 10.1111/all.14838
sha: 77f5b5e8d5a622b272b4c7deb110ffbe65f7d20c
doc_id: 971490
cord_uid: ylj5fdfs

Older adults, especially men and/or those with diabetes, hypertension and/or obesity, are prone to severe COVID‐19. In some countries, older adults, particularly those residing in nursing homes, have been prioritised to receive COVID‐19 vaccines due to high risk of death. In very rare instances,the COVID‐19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA‐EAACI‐EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society)Working Group has proposed some recommendations for older adults receiving the COVID‐19 vaccines. Anaphylaxis to COVID‐19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients.

Older adults (over 65 years of age), 1,2 especially men and/or those with diabetes, 3 hypertension 4 and/or obesity 5 , are prone to severe COVID-19. Older men have more severe COVID-19 infections than women of the same age. [6] [7] [8] [9] Frailty is a risk factor for mortality from COVID-19 10, 11 . The population residing in nursing homesgenerally includes subjects who are both old and suffering from multimorbidity.

Residential context increases social contacts in the same setting. A large number of COVID-19-related deaths have been reported in nursing homes [12] [13] [14] [15] [16] , and recommendations to control COVID-19 in these settings have been issued. [16] [17] [18] Discharge from hospitals to nursing homes also puts residents at risk.

In some countries, older adults, particularly those residing in nursing homes, have been prioritised to receive COVID-19 vaccines due to high risk of death.

There are several peculiarities of the immune response to COVID-19 vaccines in older people. For example, vaccine-induced local and systemic reactogenicity -such as pain, fatigue, headache or fever -was generally lower in older recipients of mRNA-based COVID-19 than in younger ones during the clinical trial phases.

However, in very rare instances, COVID-19 vaccines can induce anaphylaxis [19] [20] [21] . Anaphylaxis in older people is not uncommon and is often more severe than in younger adults 22 . Vaccinations are known to cause anaphylaxis, although very rarely. 23, 24 The benefit of the vaccination clearly outweighs the risk of severe anaphylaxis reaction to the COVID-19 vaccines, even in older people suffering from severe allergic diseases.

The staff responsible for vaccinating in nursing homes may come from different educational backgrounds and include primary care staff or geriatricians who may not have had much experience in the management of anaphylaxis. Potential rapid evaluation and differential diagnosis of symptoms are therefore important.

Moreover, in many countries, the equipment is insufficient in nursing homes (e.g., lack of emergency medication, no possibility to provide IV therapy or infusion).

An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, European Geriatric Medicine Society)Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines.

This article is protected by copyright. All rights reserved Several adverse reactions are reported for the COVID-19 vaccines. They are classified into very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), and not known (cannot be estimated from the available data). Currently, due to lack of sufficient confirmed data, anaphylaxis/hypersensitivity are included under the "not known" category. The COVID-19 vaccines will be administered to billions of individuals worldwide and there are raised concerns that severe adverse reactions -requiring continuous alertness and careful management -might sometimes occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) stated its position for preliminary recommendations that are to be revised as soon as more data emerge. 21, 27 , 29

The European Anaphylaxis Registry includes data from 1,123 patients over 65 years of age with anaphylactic reactions. These data are provided by tertiary referral centres specialised in allergology and/or dermatology in Austria, Bulgaria, France, Germany, Italy, Poland, Spain and Switzerland. 30 In the registry, anaphylactic symptoms were similar in younger adults and older people, but their frequency differed: cardiovascular symptoms occurred more frequently in older people (80% compared to 75% in adults). This confirmed previous observations that in patients presenting with anaphylaxis at the Emergency Department, an age of 65 or older was associated with an increased likelihood of cardiovascular symptoms. 31 A major cardiovascular symptom was loss of consciousness (33%), while dizziness and

This article is protected by copyright. All rights reserved tachycardia were more prevalent in younger adults. Cardiac arrest occurred in 3% of older persons and in 2% of younger adults. The skin was the most frequently involved organ system. Urticaria and angioedema are two clinical manifestations of anaphylaxis and usually appear before other symptoms. The severity of anaphylactic reactions in older patients without skin symptoms was increased in comparison to younger adults. Gastrointestinal symptoms occurred in a similar proportion in both groups. The respiratory system,especially dyspnoea, was less frequently affected in older persons (63% compared to 70% in younger adults). However, cyanosis, syncope and dizziness are highly predictive of shock development in older people. Severe anaphylactic reactions, including grade III (47%) and grade IV (4%) of the anaphylaxis Ring and Messmer classification, 32 were more prevalent in people aged 65+.

This registry indicates that symptoms are similar in younger/middle-aged adults and older people but that they are more severe in the older age group (Figure 1 ). Adrenaline was administered in 30% of older patients. Hospitalisation was required in 60%, and 19% of older patients were treated in an intensive care unit (ICU). Significantly more older people as compared to younger and middle-aged adults with grade II and III anaphylaxis needed hospitalisation and ICU care 32 ( Figure 1 and Table 1 ). Considering different triggers of anaphylaxis, higher age has been consistently associated with increased rates of fatal drug anaphylaxis. This may be related to an increased prevalence of drug allergy following an increased drug exposure, and/or to an increased underlyingcardiovascular vulnerability. 33 Anaphylaxis is usually graded according to Ring and Messmer 32 (Table 1) , although there are proposals for new grading systems 34,35 .However, WHO and regulatory authorities recommend the use of the Brighton Collaboration Anaphylaxis Working Group for pharmacovigilance registers. 23 Classification according to the most severe symptom is mandatory.

In the European Anaphylaxis Registry, older age (excluding the confounding factor of concomitant cardiovascular or other diseases) and concomitant mastocytosis 38 werethe most important predictors for an increased risk of severe anaphylaxis. 30, 37, 39, 40 Hereditary alpha-tryptasemia is another risk factor.

Anaphylaxis is more severe and has an increased risk of death in patients with coronary artery disease because both the number of mast cells and the production of their vasoactive mediators are increased in ischaemic cardiomyopathy. In addition, atherosclerotic lesions make coronary arteries more susceptible to

This article is protected by copyright. All rights reserved the effects of mast cell-and basophil-derived mediators, 41 and individuals with an underlying vascular illness less tolerant to hypoxia and hypotension during anaphylaxis.

In older people from the registry, cardiovascular diseases, thyroid diseases and cancer were more common than in younger adults. 37

In the European Anaphylaxis Registry, medications associated with an increased risk of severe anaphylaxis risk cofactors -such as ACE-inhibitors (angiotensin converting enzyme inhibitor), AT-2-antagonists (Angiotensin II receptor type 2), ß-blockers, acetylcholine, and proton pump inhibitors -were significantly more frequently prescribed in older people (57%) than in younger adults (18%). 39 Independent of the age of the patient, ß-blockers and ACE inhibitors administered close to allergen immunotherapy increased the risk of developing severe anaphylaxis, while aspirin and AT-2 did not. 39 However, a systematic review with low quality evidence showed that ß-blockers and ACE inhibitors increased the severity of anaphylaxis, due to differences in confounders, in particular cardiovascular diseases 42 .

It is important to highlight the significant number of older patients who are being treated with anxiolytics, antidepressants, hypnotics and other drugs that can act on the central nervous system and alter the individual person's recognition and perception of the symptoms and signs of anaphylaxis.

The Airway, Breathing, Circulation, Disability, Exposure (ABCDE) algorithm is applicable in all clinical emergencies for immediate assessment and treatment 43 (Figure 2 ). If anaphylaxis is suspected, every patient should receive rapid evaluation of vital functions via ABCDE, and problems should be addressed in a targeted manner.

The aims of the ABCDE approach are 43 :  toprovide life-savingtreatment  to break down complex clinical situations into more manageable parts  to serve as an assessment and treatment algorithm

This article is protected by copyright. All rights reserved  to establish common situational awareness among all treatment providers  to buy time to establish a final diagnosis and treatment.

Guidelines from EAACI 44 and the World Allergy Organization 45 recommend prompt intramuscular injection of adrenaline as first-line therapy for anaphylaxis. Adrenaline can counteract most severe symptoms of anaphylaxis in older people 22 . Intramuscular administration of adrenaline, if possible using a ready-to-use preparation or auto-injector, is recommended. The initial dose is 0.3-0.5 ml of a 1:1000 dilution (1 mg/ml). The patient should then be monitored, and, if ineffective, the administration can be repeated after at least a 5-minute interval 22 . The subcutaneous route should not be used because the vasoconstrictor effect of adrenaline injected into the subcutaneous tissue potentially delays adrenaline absorption 46 . The intra-vascular route should be avoided since most cardiovascular adverse events of adrenaline appear to occur via this route 47 . Intravenous continuous infusion should only be given to patients not responding to intramuscular injection under careful ECG monitoring 44 .

During an anaphylactic reaction occurring in patients with cardiovascular disease, the benefits versus the harms of adrenaline injection should be weighed carefully. The presence of cardiovascular disease does not exclude the use of adrenaline in anaphylaxis since no other medications have life-saving effects in this medical emergency. 41 There are no absolute contraindications to the prescription of self-injectable adrenaline in older patients or in those with a cardiovascular disease who are at risk of anaphylaxis. Serious adverse effects, such as ventricular arrhythmias, hypertension or myocardial ischemia, have not been reported following the use of adrenaline autoinjectors. 48 However, older patients with anaphylaxis seem to be more likely to experience a cardiac adverse event after adrenaline injection, with those older than 80 years having the highest risk. 49

Regular intake of multiple medications is frequent in older patients (polypharmacy). Co-medication may modify the evolution of anaphylaxis, and also its management.The therapeutic effect of adrenaline may be blunted by ß-blockers. In this situation, if epinephrine is not effective, glucagon can be administered intravenously, as it has a mechanism of action independent of the ß-receptors. 50, 51 Older patients may be using sedating or psychotropic drugs, and these could affect the recognition and perception of anaphylactic symptoms. 52

This article is protected by copyright. All rights reserved  Vaccination should always be performed in a healthcare setting, which may be a mobile unit  All necessary aids and rescue drugs must be available in the vaccination setting  All medical personnel assigned should receive training and be able to immediately recognise and manage an emergency situation, including anaphylaxis.

As proposed in three ARIA-EAACI Position Papers on anaphylaxis to COVID-19 vaccines, recommendations have been adapted for older patients. 21, 28, 29  Patients with a history of allergic diseases should not be excluded from the vaccines as the exclusion of all these patients from vaccination may have a significant impact on reaching the goal of herd immunity. However, without an allergist advice, a previously known allergy to the substances contained in the vaccines presents a contraindication, as well as a reaction to the first dose of the COVID-19 vaccine, which presents a contraindication for administering the second dose. A previous severe anaphylactic reaction to other vaccines or drugs does not represent a contraindication.However, consultation with an allergistmay be helpful to assess the individual situation.

 Healthcare practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognise and treat anaphylaxis properly, particularly since older patients tend to have more severe anaphylactic symptoms. If a severe reaction occurs, hospitalisation may be considered more readily than for younger adults after first-aid action. In this study, hospitalization and ICU were differentiated between adults and old age people 

Accepted Article

University Hospital 'Sv Ivan Rilski

Afula, and Rappaport Faculty of Medicine

School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London and Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London,and Children's Allergy Service, Evelina London Children's Hospital Guy'sand St Thomas' Hospital

National age and coresidence patterns shape COVID-19 vulnerability

Case fatality rate analysis of Italian COVID-19 outbreak

Coronavirus disease 2019 (COVID-19): we don't leave women alone

Accepted Article This article is protected by copyright. All rights reserved

Age and Multimorbidity Predict Death Among COVID-19

Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

Coronavirus and Obesity: Could Insulin Resistance Mediate the Severity of Covid-19 Infection? Front Public Health

Biological sex impacts COVID-19 outcomes

Impact of sex and gender on COVID-19 outcomes in Europe

Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases

Excess mortality during the COVID-19 outbreak in Italy: a two-stage interrupted time-series analysis

Clinical frailty scale and mortality in COVID-19: A systematic review and dose-response meta-analysis

The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study

Epidemiology of Covid-19 in a Long-Term Care Facility in King County

Efficacy of a Test-Retest Strategy in Residents and Health Care Personnel of a Nursing Home Facing a COVID-19 Outbreak

Mass Screening for SARS-CoV-2 Infection among Residents and Staff in Twenty-eight Long-term Care Facilities in Fulton County

Is There a Link between Nursing Home Reported Quality and COVID-19 Cases? Evidence from California Skilled Nursing Facilities

Nursing Home Care in Crisis in the Wake of COVID-19

Commentary: COVID in Care Homes-Challenges and Dilemmas in Healthcare Delivery

Interim EuGMS guidance to prepare European Long-Term Care Facilities for COVID-19

mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Approach

Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines -an EAACI-ARIA position paper

Importance of hypersensitivity in adverse reactions to drugs in the elderly

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data

Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System

COVID-19 vaccine safety update

Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol? Allergy

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine

Potential allergenic components of the mRNA-1273 vaccine for COVID-19: possible roles for polyethlene glycol and IgG-mediated complement activation

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Anaphylaxis in Elderly Patients-Data From the European Anaphylaxis Registry

Anaphylaxis in emergency department patients 50 or 65 years or older

Incidence and severity of anaphylactoid reactions to colloid volume substitutes

Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations

Accepted Article This article is protected by copyright. All rights reserved 34

The urgent need for a harmonized severity scoring system for acute allergic reactions

Guideline for acute therapy and management of anaphylaxis: S2 Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Association of German Allergologists (AeDA), the Society of Pediatric Allergy and Environmental Medicine (GPA), the German Academy of Allergology and Environmental Medicine (DAAU), the German Professional Association of Pediatricians (BVKJ), the Austrian Society for Allergology and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Anaesthesiology and Intensive Care Medicine (DGAI), the German Society of Pharmacology (DGP), the German Society for Psychosomatic Medicine (DGPM), the German Working Group of Anaphylaxis Training and Education (AGATE) and the patient organization German Allergy and Asthma Association (DAAB)

Detection of KIT D816V mutation in patients with severe anaphylaxis and normal basal tryptase-first data from the Anaphylaxis Registry (NORA)

Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients

Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry

Anaphylaxis and cardiovascular disease: therapeutic dilemmas

Relationship Between Anaphylaxis and Use of Beta-Blockers and Angiotensin-Converting Enzyme Inhibitors: A Systematic Review and Meta-Analysis of Observational Studies

Initial assessment and treatment with the Airway, Breathing, Circulation, Disability, Exposure (ABCDE) approach

Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology

Accepted Article This article is protected by copyright. All rights reserved

update of the evidence base: World Allergy Organization anaphylaxis guidelines

Epinephrine and its use in anaphylaxis: current issues

Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine

Self-medication of anaphylactic reactions due to Hymenoptera stings-an EAACI Task Force Consensus Statement

Age-related cardiovascular outcomes in older adults receiving epinephrine for anaphylaxis in the emergency department

Glucagon for Refractory Anaphylaxis

A Rapid review of advanced life support guidelines for cardiac arrest associated with anaphylaxis. Resuscitation

Recognition and first-line treatment of anaphylaxis

*** ***